Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Multiple Sclerosis Pipeline Review Report of 178 Companies


News provided by

ReportsnReports

14 Jul, 2016, 10:00 GMT

Share this article

Share toX

Share this article

Share toX

PUNE, India, July 14, 2016 /PRNewswire/ --

ReportsnReports.com adds "Multiple Sclerosis - Pipeline Review, H1 2016" market research report to its store providing an overview of the Multiple Sclerosis's therapeutic pipeline complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Multiple Sclerosis and special features on late-stage and discontinued projects.

Complete report on H1 2016 pipeline review of Multiple Sclerosis with 259 market data tables and 17 figures, spread across 903 pages is available at http://www.reportsnreports.com/reports/622293-multiple-sclerosis-pipeline-review-h1-2016.html .

Multiple Sclerosis Multiple sclerosis (MS) is a potentially debilitating disease in which body's immune system eats away at the protective sheath (myelin) that covers nerves. Damage to myelin causes interference in the communication between brain, spinal cord and other areas of body. Symptoms include numbness or weakness in one or more limbs, double vision or blurring of vision, tingling or pain in parts of body, fatigue and slurred speech. The predisposing factors include age, gender, family history and certain infections.   The molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 12, 29, 31, 166, 36 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 3, 38 and 2 molecules, respectively.

Some of the companies discussed in this Multiple Sclerosis Pipeline Review, H1 2016 market research report include 4D Pharma Plc, 4SC AG, AB Science SA, AbbVie Inc., Ablynx NV, Acorda Therapeutics, Inc., Actelion Ltd, Addex Therapeutics Ltd, Adhaere Pharmaceuticals, Inc., Aegis Therapeutics, LLC, Affectis Pharmaceuticals AG, Athersys, Inc., Axxam SpA, Baliopharm AG, Bio-Cancer Treatment International Limited, BioAegis Therapeutics, Inc., BIOCAD, Biocon Limited, Biogen, Inc., Biogenomics Limited, Biokine Therapeutics Ltd., Biomar Microbial Technologies, Bionature E.A. Ltd., Bioncotech Therapeutics S.L., Bionovis SA, Bionure Farma, S.L., Biovista Inc., Bird Rock Bio, Inc., Bolder Biotechnology, Inc., BrainStorm Cell Therapeutics Inc., C4X Discovery Holdings PLC, Caladrius Biosciences, Inc., CASI Pharmaceuticals Inc., Catalyst Pharmaceuticals, Inc., Celgene Corporation, Cell Cure Neurosciences, Ltd., Cell2B S.A., Cellceutix Corporation, Chong Kun Dang Pharmaceutical Corp., Cognosci, Inc., Coherus BioSciences, Inc., Commence Bio, Inc., Compugen Ltd., Connexios Life Sciences Pvt. Ltd., Critical Outcome Technologies Inc., CuraVac, Inc., Cyxone AB, Dimerix Bioscience Pty Ltd, Eisai Co., Ltd., Endece, LLC, Euroscreen S.A., Evgen Pharma Plc, Evotec AG, F. Hoffmann-La Roche Ltd., Flex Pharma, Inc., Forward Pharma A/S, FPRT Bio Inc., Gemac, Genervon Biopharmaceuticals, LLC, ,GeNeuro SA, Genzyme Corporation, GlaxoSmithKline Plc, Glialogix, Inc., Hansa Medical AB, Hanwha Chemical Corporation, Harbor Therapeutics, Inc., HitGen LTD, Hutchison MediPharma Limited, Iltoo Pharma, Immune Response BioPharma, Inc., ImmuNext, Inc., Immungenetics AG, InDex Pharmaceuticals AB, Innate Immunotherapeutics Ltd, Inovio Pharmaceuticals, Inc., Io Therapeutics, Inc., Jyant Technologies, Inc., Kadimastem Ltd., Kadmon Corporation, LLC, KAHR medical Ltd., KaloBios Pharmaceuticals, Inc., Kareus Therapeutics, SA, Karo Pharma AB, Karyopharm Therapeutics, Inc., Kezar Life Sciences, Inc., Kineta, Inc., Kyorin Pharmaceutical Co., Ltd., Lead Discovery Center GmbH, LFB S.A., Lipocure Ltd., MacroGenics, Inc., MAKScientific, LLC, Mallinckrodt Plc, Mapi Pharma Ltd., Marathon Pharmaceuticals, LLC, MedAnnex Ltd, MedDay SA, Medestea Research & Production S.p.A., MedImmune, LLC, Meiji Seika Pharma Co., Ltd., Merck KGaA, Meta-IQ ApS, Mitochon Pharmaceuticals, Inc., Mitsubishi Tanabe Pharma Corporation, MorphoSys AG, Neuralstem, Inc., Neuren Pharmaceuticals Limited, Neurotec Pharma SL, New World Laboratories, Inc., Novartis AG, NovImmune SA, Nuevolution AB, Octapharma AG, Omeros Corporation, OncoImmune, Inc., Opexa Therapeutics, Inc., OPKO Health, Inc., OSE Immunotherapeutics, Parvus Therapeutics, Inc., Peptinov SAS, Pfenex Inc., Pfizer Inc., PharmaEssentia Corporation, PharmatrophiX, Inc., Pharmaxis Limited, Pieris Pharmaceuticals, Inc., Plexxikon Inc., ProNoxis AB, Prothena Corporation Plc, Q Therapeutics, Inc., ReceptoPharm, Inc., RedHill Biopharma Ltd., RegeneRx Biopharmaceuticals, Inc., Regenesance BV, Resverlogix Corp., ReveraGen BioPharma, Inc., Rigel Pharmaceuticals, Inc., SanBio, Inc., Santhera Pharmaceuticals Holding AG, Sareum Holdings Plc, SK Biopharmaceuticals Co., Ltd., Sorrento Therapeutics, Inc., Symic Biomedical, Inc., Synthon Holdings BV, Targazyme, Inc., Teikoku Pharma USA, Inc., Teva Pharmaceutical Industries Ltd., Therapix Biosciences Ltd, TikoMed AB, Toleranzia AB, Topas Therapeutics GmbH, TxCell SA, Vaccinex, Inc., Vakzine Projekt Management GmbH, Vertex Pharmaceuticals Incorporated, Virogenomics BioDevelopment, Inc., Vitae Pharmaceuticals, Inc., VivaCell Biotechnology Espana S.L., Xenetic Biosciences (UK) Limited, XL-protein GmbH, Yungjin Pharm. Co., Ltd. and Zydus Cadila Healthcare Limited. Order a copy of Multiple Sclerosis - Pipeline Review, H1 2016 market research report @ http://www.reportsnreports.com/Purchase.aspx?name=622293 .

Another newly published market research report titled on Wegener Polyangiitis - Pipeline Review, H1 2016 reviews pipeline therapeutics for Wegener Polyangiitis by companies and universities/research institutes based on information derived from company and industry-specific sources. Wegener Polyangiitis Pipeline market research report of 60 pages is available at http://www.reportsnreports.com/reports/622313-wegener-polyangiitis-pipeline-review-h1-2016.html .

Explore more reports on Pharmaceuticals.

About Us: 

ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.

Contact:
Ritesh Tiwari
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
Maharashtra, India.
+ 1 888 391 5441
sales@reportsandreports.com

Connect With Us on:
Facebook: https://www.facebook.com/ReportsnReports/
LinkedIn: https://www.linkedin.com/company/reportsnreports
Twitter: https: //twitter.com/marketsreports
G+ / Google Plus: https://plus.google.com/111656568937629536321/posts
RSS/Feeds:  http://www.reportsnreports.com/feed/l-latestreports.xml

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.